Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA.
Oncologist. 2011;16 Suppl 1:20-2. doi: 10.1634/theoncologist.2011-S1-20.
A personalized approach to breast cancer management is increasingly possible with state of the art diagnostics and treatments. However, many challenges still exist in choosing the right therapeutic strategy and the right dosing for a specific patient population. Biomarkers such as estrogen receptor, progesterone receptor, and HER-2 status are used to tailor therapy, but success rates with targeted therapy suggest that appropriate patient populations still require greater definition. The introduction of the genomic era has likewise advanced the ability to offer a tailored approach to breast cancer management, but much work is still needed in this area as well. Microarray-based gene expression profiles have demonstrated initial promise, but we need a better understanding of more complex tumor signaling pathways. Strategies include annotated tumor specimens, next-generation gene sequencing, proteomics, and metabolomics. An individualized approach to breast cancer management has the potential to offer clear clinical benefits and the ability to bring more tailored, cost-effective strategies to the market. The current issues facing the delivery of individualized breast cancer care will be the focus of this discussion.
随着先进的诊断和治疗方法的出现,乳腺癌管理的个性化方法变得越来越可行。然而,在选择正确的治疗策略和特定患者群体的正确剂量方面仍然存在许多挑战。雌激素受体、孕激素受体和 HER-2 状态等生物标志物用于定制治疗,但靶向治疗的成功率表明,适当的患者群体仍需要进一步明确。基因组时代的引入同样提高了为乳腺癌管理提供定制方法的能力,但在这一领域仍需要做更多的工作。基于微阵列的基因表达谱已经显示出初步的希望,但我们需要更好地了解更复杂的肿瘤信号通路。策略包括注释肿瘤标本、下一代基因测序、蛋白质组学和代谢组学。乳腺癌管理的个体化方法有可能带来明显的临床益处,并能够为市场带来更具针对性、更具成本效益的策略。本讨论将重点关注个性化乳腺癌护理提供所面临的当前问题。